Question | Discussion | References | CME Credit

Case 3: References

  1. Plosker GL, Noble S. Indinavir: a review of its use in the management of HIV infection. Drugs. 1999;58:1165-203.
    [The following link will open in a new window. PubMed Abstract]
  2. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997;337:734-9.
    [The following link will open in a new window. PubMed Abstract]
  3. Gulick RM, Mellors JW, Havlir D, et al. 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann Intern Med. 2000;133:35-9.
    [The following link will open in a new window. PubMed Abstract]
  4. Reiter WJ, Schon-Pernerstorfer H, Dorfinger K, Hofbauer J, Marberger M. Frequency of urolithiasis in individuals seropositive for human immunodeficiency virus treated with indinavir is higher than previously assumed. J Urol. 1999;161:1082-4.
    [The following link will open in a new window. PubMed Abstract]
  5. Saltel E, Angel JB, Futter NG, Walsh WG, O’Rourke K, Mahoney JE. Increased prevalence and analysis of risk factors for indinavir nephrolithiasis. J Urol. 2000;164:1895-7.
    [The following link will open in a new window. PubMed Abstract]
  6. Kopp JB, Miller KD, Mican JM, et al. Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med. 1997;127:119-25.
    [The following link will open in a new window. PubMed Abstract]
  7. Boubaker K, Sudre P, Bally F, Vogel G, Meuwly J, Glauser MP, Telenti A. Changes in renal function associated with indinavir. AIDS. 1998;12:F249-54.
    [The following link will open in a new window. PubMed Abstract]
  8. Dieleman JP, Gyssens IC, van der Ende ME, de Marie S, Burger DM. Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. AIDS. 1999;13:473-478.
    [The following link will open in a new window. PubMed Abstract]
  9. Voigt E, Wickesberg A, Wasmuth J-C, et al. First-line ritonavir/indinavir 100/800 mg twice daily plus nucleoside reverse transcriptase inhibitors in a German multicentre study: 48-week results. HIV Med. 2002;3:277-282.
    [The following link will open in a new window. PubMed Abstract]
  10. Lichterfeld M, Nischalke HD, Bergmann F, et al. Long-term efficacy and safety of ritonavir/indinavir at 400/400 mg twice a day in combination with nucleoside reverse transcriptase inhibitors as first line antiretroviral therapy. HIV Med. 2002;3:37-43.
    [The following link will open in a new window. PubMed Abstract]
  11. Malavaud B, Dinh B, Bonnet E, Izopet J, Payen JL, Marchou B. Increased incidence of indinavir nephrolithiasis in patients with hepatitis B or C virus infection. Antivir Ther. 2000;5:3-5.
    [The following link will open in a new window. PubMed Abstract]
  12. Martinez E, Leguizamon M, Mallolas J, Miro JM, Gatell JM. Influence of environmental temperature on incidence of indinavir-related nephrolithiasis. Clin Infect Dis. 1999;29:422-5.
    [The following link will open in a new window. PubMed Abstract]
  13. Gagnon RF, Alli AI, Edwardes MD, Watters AK, Tsoukas CM. Low urine pH is associated with reduced indinavir crystalluria in indinavir-treated HIV-infected individuals. Clin Nephrol. 2006;65:13-21.
    [The following link will open in a new window. PubMed Abstract]
  14. Daudon M, Estepa L, Viard JP, Jungers P. Urinary stones in HIV-1 positive patients treated with indinavir. Lancet. 1997;349:1294-5.
    [The following link will open in a new window. PubMed Abstract]
  15. Tashima K, Horowitz JD, Rose S. Indinavir nephropathy. N Engl J Med. 1997;336:138-40.
    [The following link will open in a new window. PubMed Abstract]
  16. Hanabusa H, Tagami H, Hataya H. Renal atrophy associated with long-term treatment with indinavir. N Engl J Med. 1999;340:392-3.
    [The following link will open in a new window. PubMed Abstract]
  17. Gagnon RF, Tecimer SN, Watters AK, Hatzakis GE, Tsoukas CM. The natural history of leukocyturia associated with indinavir treatment in HIV+ individuals. Am J Nephrol. 2000;20:448-54.
    [The following link will open in a new window. PubMed Abstract]
  18. Dieleman JP, van Rossum AM, Stricker BC, et al. Persistent leukocyturia and loss of renal function in a prospectively monitored cohort of HIV-infected patients treated with indinavir. J Acquir Immune Defic Syndr. 2003;32:135-42.
    [The following link will open in a new window. PubMed Abstract]
  19. Gentle DL, Stoller ML, Jarrett TW, Ward JF, Geib KS, Wood AF. Protease inhibitor-induced urolithiasis. Urology. 1997;50:508-511.
    [The following link will open in a new window. PubMed Abstract]

[Back to Case 3 Question | Back to Discussion]

CME Credit | Back to Top